The Complete Guide to Toceranib (Palladia) for Dogs

ImmunityQ&AMeongsiljang Veterinary Advisory Board

Toceranib (Palladia) is an oral targeted cancer drug approved for treating mast cell tumors in dogs. We’ve summarized its effectiveness, side effects, and dosing instructions in a way that’s easy for pet owners to understand.

What is Toceranib (Palladia)?

A bottle of oral chemotherapy medication placed next to the puppy

Toceranib (brand name Palladia) is an orally administered targeted anticancer drug officially approved for the treatment of canine mast cell tumors. The key advantage is that it can be given at home in tablet form. Unlike traditional intravenous chemotherapy, pet owners can administer it themselves, and it selectively blocks tyrosine kinase, a signaling enzyme involved in tumor growth, thereby simultaneously inhibiting cancer cell proliferation and angiogenesis.

What Cancers is it Used For?

The officially approved indication is for recurrent or inoperable mast cell tumors (stages 2–3). However, off-label use has been reported in studies involving certain solid tumors, such as anal sac adenocarcinoma and osteosarcoma. Since evidence supporting its use for tumors other than mast cell tumors remains limited, individual assessment by a veterinary oncologist regarding efficacy and safety is particularly important. Your veterinarian will make the decision on whether to use this treatment after comprehensively evaluating the tumor type and stage, as well as your dog’s overall health status.

Comparison of Toceranib with Traditional Chemotherapy

Item	Conventional intravenous chemotherapy	Toceranib (Palladia)
Method of administration	Hospital admission / intravenous injection	Oral administration at home
Frequency	Hospital visits every 2–3 weeks	Every other day
Main action	Attacks rapidly dividing cells	Blocks cancer growth signals and blood vessel formation
Burden on owner	Hospitalization and transportation burden	Can be administered at home
Monitoring	Blood test each cycle	Blood and proteinuria tests every 2–4 weeks

The actual choice depends on the tumor type, presence of metastasis, and the dog's overall condition.

How Are Dosing and Administration Determined?

Toceranib is typically administered orally on an every-other-day schedule (e.g., Monday, Wednesday, Friday). The specific dosage is determined by your veterinarian based on your pet’s weight and overall health, and may be reduced or temporarily paused if side effects occur. The tablet should be given whole—do not crush or break it—and can be administered with or without food. Be sure to wash your hands thoroughly after handling the medication.

One oral chemotherapy pill, prepared alongside your dog’s regular food

Handling Precautions for Pet Owners

Toceranib is a cytotoxic medication, so please follow these guidelines to protect your family members. Avoid handling the tablets with bare hands; wear gloves or wash your hands immediately after administration. Pregnant or breastfeeding individuals, as well as children, should not handle the medication. For 24 hours after administration, your dog’s urine, feces, and vomit may contain residual drug components, so wear gloves and dispose of them in plastic bags. Store the medication in its original container, out of reach of children.

Checklist of Major Side Effects

According to veterinary pharmacology textbooks, toceranib has a narrow therapeutic index (safety margin), so consistent monitoring is essential. - Gastrointestinal symptoms: Diarrhea, vomiting, and decreased appetite are the most common side effects. - Weight loss: This may occur alongside a reduced appetite. - Lethargy: Your pet may appear more lethargic and less active than usual. - Proteinuria: While there are no visible symptoms, this can be detected through urinalysis. - Elevated liver enzymes: These changes are only visible in blood tests. - Bone marrow suppression: A decrease in white blood cells, red blood cells, and platelets can increase the risk of infection or anemia.

A guardian watching over their dog as it rests at home.

Contact Your Veterinarian Immediately for These Symptoms

Contact your veterinarian immediately if you notice any of the following: bloody stool, black tarry stool, repeated vomiting, loss of appetite lasting more than 24 hours, severe lethargy, difficulty breathing, pale or yellow gums, or sudden lameness. These signs may indicate serious side effects such as gastrointestinal bleeding, liver toxicity, or worsening proteinuria. Do not skip the next dose on your own; always follow your veterinarian's instructions.

How Are Regular Check-ups Conducted During Treatment?

While your pet is taking toceranib, regular blood tests, urinalysis (to check for proteinuria), and physical exams are essential. During the initial phase of treatment, these checks should be done at frequent intervals, and the schedule can be gradually adjusted once their condition stabilizes. Imaging studies such as X-rays, ultrasounds, or CT scans are also performed periodically to evaluate the tumor’s response. Depending on the test results, the dosage may be adjusted, or a temporary break from the medication (a drug holiday) may be recommended. Please work with your veterinarian to establish a specific testing schedule and ensure you keep all appointments, as this is crucial for safe, long-term treatment.

Home Care Points

Please keep a brief daily log of your dog’s condition during treatment. - Food intake: Percentage of normal appetite - Stool status: Consistency (soft or bloody), presence of blood, and frequency - Activity level: Willingness to walk and responsiveness to play - Weight: Measured once a week at the same time of day - Medication log: Date, time, and any missed doses This record is essential for your veterinarian to adjust dosages during follow-up visits. It’s also helpful to save photos or short videos alongside your notes.

A pet owner recording medication administration while sitting next to their dog

Drugs That Should Not Be Used Together

Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase the risk of gastrointestinal toxicity when used concurrently with high-dose steroids, so careful clinical judgment is required. Caution is also warranted when combining this medication with other chemotherapeutic agents or immunosuppressants. Please inform your attending veterinarian of all medications and supplements your dog is currently taking, including those prescribed by other clinics, joint supplements, and heart medications. Do not add or discontinue any medications on your own without veterinary guidance.

Reviewed by a veterinarian

Dr. Tony — Punnawat Phongkittirak

Veterinarian

A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.

Frequently Asked Questions

Is toceranib intended as a curative treatment?

The primary goal is not necessarily a cure, but rather to shrink the tumor and slow its progression in order to maintain quality of life. According to a randomized double-blind study (London et al., 2009), an objective response—defined as tumor shrinkage or stabilization—was observed in approximately 37% of dogs with mast cell tumors.

What should I do if I miss a dose?

If you remember, give one pill right away. But if it's close to the next scheduled dose, skip the missed one and continue with the regular schedule. Never give a double dose, and be sure to let your vet know about any missed doses during your next visit.

When will I start seeing the treatment take effect?

Typically, we assess the tumor’s response through imaging and palpation 4 to 6 weeks after treatment. In some cases, shrinkage may be observed as early as 2 to 3 weeks, while in others, if there is no effect, we may switch to a different treatment approach.

Can this be used for cats too?

Toceranib is officially approved for use in dogs. While its off-label use for feline mast cell tumors has been discussed, its efficacy has not yet been confirmed by large-scale prospective studies. Additionally, some studies targeting certain tumors, such as feline injection-site sarcomas (FISS), have shown no measurable clinical response. Therefore, whether to use it in cats should be carefully decided after consulting with a veterinary oncologist.

How long is the treatment period?

It depends on the tumor’s response and any side effects. If the response is favorable and side effects are manageable, the medication may be continued for several months to over a year. Your veterinarian will decide whether to continue treatment based on regular check-up results.

Primary vs. Secondary Veterinary Hospitals: A Comparison

Comparing Dog Vaccine Types (3-way, 5-way, 7-way): Differences and How to Choose

Pet Insurance Enrollment Timing Comparison: When Is the Most Advantageous Time to Enroll?

What is Canine Squamous Cell Carcinoma? — Early Signs and Responses You Should Not Miss

What Are Spleen Tumors in Dogs? — Differences Between Hemangiosarcoma and Nodular Types and Treatment Approaches

Does spaying your dog help prevent mammary tumors? — Breakdown of risk by timing

Soft Tissue Sarcoma in Dogs: Frequently Asked Questions — Key Information Every Pet Owner Should Know

Is My Dog’s Cough a Sign of Lung Cancer? — Symptoms of Lung Metastasis and When to Visit the Vet

How to Care for Your Dog After a Splenectomy — A Complete Guide to Recovery Precautions

Can dog cancer pain be reduced at home? — Palliative care and when to visit the vet

References

[1] Plumb's Veterinary Drug Handbook, 10th Ed — Toceranib (Palladia)

[2] London CA et al., Multicenter, placebo-controlled, double blind, randomized study of oral toceranib phosphate (SU11654) for canine mast cell tumor, Clinical Cancer Research 15, 3656-3865, 2009

[3] Therapeutic Strategies in Veterinary Oncology — Signal Transduction Inhibitors chapter

[4] Mitchell L, Thamm DH, Biller BJ — Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer, J Vet Intern Med 26(2), 355-362, 2012